Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.

CAS：417716-92-8
中文别名：乐伐替尼;
英文别名：E7080,E 7080;Lenvatinib (E7080);Lenvatinib;4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide;
分子式：C21H19ClN4O4
分子量：426.853
精确质量：426.109
Psa：115.57
Logp：5.2361

MDL号：MFCD16038644

密度：1.469g/cm3
沸点：627.242ºC at 760 mmHg
闪点：333.144ºC
折射率：1.697